Updates
Last chance to invest! Campaign ends tonight
8 months agoThank you again to all of our investors! Our StartEngine campaign ends tonight so make sure to get in now!
20/20 Management Team
This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view 20/20’s offering circular and risks associated with this offering.
Over $500k raised!
10 months agoOver $500,000 raised! Thank you to our early adopters and community for believing in our mission.
20/20's OneTest for Firefighters featured on local TV newscast in suburban Atlanta
11 months agoEarlier this week a local newscast outside of Atlanta Georgia featured a story about how the Clayton County Fire Department has been using 20/20's OneTest to help their members screen for cancer. The 3 minute story can be viewed here:
Studies by the U.S. Centers for Disease Control have proven that firefighters have a statistically significant increase in cancer incidence and death for more than a dozen cancer types (especially those of the digestive tract.) Moreover, studies among Korean firefighters have demonstrated that annual check ups that measure several of the tumor markersin OneTest reduce death rates.
20/20's founder is a former volunteer firefighter and a co-inventor of the company's patented BioCheck kits for screening suspicious powders. See www.BioCheckInfo.com Those kits have been popular with fire departments worldwide for many years.
20/20 presents at IBM AI Symposium this week
12 months agoEarlier this week 20/20 was one of only nine start-ups invited to present at Symposium on AI for Biomedical Imaging held at IBM Research's San Jose campus. Participants at this event included R&D leaders from IBM Research, IBM Watson Health, and leading medical schools such as Stanford and Penn. 20/20's CEO Jonathan Cohen presented the company's vision for improving early cancer detection by building machine learning algorithms that combine in-vitro (lab tests) and in-vivo (imaging) diagnostics. For example, algorithms that integrate the levels of biomarkers like CA-125 and AFP (both part of our OneTest) with ultrasound should substantially boost the accuracy of ovarian and liver cancer detection respectively. At the Silicon Valley symposium we made contacts with industry and academic leaders in the field that we expect will help 20/20 execute on that vision over the coming years.
Comments ({{profileCtrl.startup.comments_count}} total)
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}